|November 26, 2012|
|06:11 EDT||GSK, SI, FLO, NOK, UBS||On the Fly: Periodicals Wrap-Up|
WALL STREET JOURNAL: Switzerland and the U.K. announced punitive measures against UBS (UBS) following the unauthorized trading scandal that led to losses of $2.3B at the bank. Swiss financial market regulator Finma said it will watch UBS's investment bank for the foreseeable future and may ask it to raise fresh capital, while the U.K. Financial Services Authority fined UBS $47.6M, the Wall Street Journal reports...Flowers Foods (FLO) could be interested in Twinkies and other products owned by Hostess Brands, and is considered a likely bidder for some of the assets owned by Hostess, the Wall Street Journal reports...REUTERS: The euro zone finance ministers and the IMF will seek to unfreeze the second bailout package for Greece today, but first need to agree if some of the official loans might eventually be forgiven to cut Greek debt, Reuters reports...GlaxoSmithKline (GSK) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare, said David Redfern, chief strategy officer, Reuters reports...BLOOMBERG: Home equity lines of credit that fueled a spending spree during the U.S.property boom are back. Following six years of declines, lending for so-called Helocs will increase 30% to $79.6B this year, the highest level since the start of the 2008 financial crisis, according to the economics research unit of Moody’s Corp. It projects a 31% jump to $104B next year, Bloomberg reports...Nokia Siemens Networks (NOK, SI) is targeting the U.S. market where Chinese rivals face political hurdles and rising data use entices carriers to spend. The venture is forgoing less lucrative deals in Africa and the Middle East, said CEO Rajeev Suri, Bloomberg reports.
News For UBS;FLO;GSK;NOK;SI From The Last 14 Days
|August 28, 2015|
|06:19 EDT||NOK||Nokia and China Huaxin sign MOU to create new venture|
Nokia and China Huaxin Post & Telecommunication Economy Development Center have signed a memorandum of understanding confirming their intention to combine Nokia's telecommunications infrastructure businesses in China and Alcatel-Lucent Shanghai Bell into a new joint venture. As agreed under the MoU, Nokia expects to hold 50% plus one share in the new joint venture, with China Huaxin holding the remaining shares. Fair value compensation would be received for the contribution of relevant assets to the joint venture. The new joint venture is conditional on and would be formed after the closing of Nokia's planned combination with Alcatel-Lucent, at which point Nokia would own 50% plus one share of ASB. The new joint venture is expected to be a strong national asset based in China capable of delivering value for both parties.Nokia China and ASB are leaders in the Chinese telecommunications infrastructure market and both are long-standing contributors to the development of China and innovation in the country. The new joint venture would have one board of directors, one management team, unified customer and business functions, and one integrated product portfolio and R&D platform. Until the closing of the proposed combination between Nokia and Alcatel-Lucent, Nokia China and ASB will continue to operate as two independent companies.
|August 27, 2015|
|18:02 EDT||UBS||U.S. may prohibit Deutsche Bank, others from managing pensions, Bloomberg says|
In correspondence dated mid-July, the U.S. Labor Department tentatively rejected requests from Deutsche Bank (DB), UBS (UBS), RBS (RBS) to manage U.S. pension funds, reports Bloomberg, citing letters between the organizations. Bloomberg notes that the Department could use the "threat of denial" to mandate stricter conditions on pension management. Reference Link
|06:23 EDT||UBS||Goldman hiring 'several hundred' employees for Warsaw units, Reuters reports|
Subscribe for More Information
|August 26, 2015|
|17:06 EDT||GSK||Gilead AMBITION study results published in New England Journal of Medicine |
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
|August 24, 2015|
|13:15 EDT||GSK||FDA expands use of Novartis' Promacta to include children ages 1 and older|
Ligand Pharmaceuticals (LGND) announced that the FDA has approved an expanded use for Promacta, a Novartis (NVS) product, to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was acquired by Novartis in March from GlaxoSmithKline (GSK). Promacta was discovered as a result of research collaboration between GSK and Ligand Pharmaceuticals and was developed by GSK. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 years of age and older and in 2008 for use in adult patients with the same condition. The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase 3 clinical trial in this patient population. Treatment with Promacta significantly increased and sustained platelet counts among pediatric patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids. Promacta should be used only in those whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
|August 21, 2015|
|12:18 EDT||NOK||Microsoft to cut up to 2,300 jobs in Finland, Reuters reports|
Microsoft (MSFT) will cut up to 2,300 jobs in Finland and close Nokia's (NOK) former handset product development unit in Salo, Reuters reports. The cuts are part of Microsoft's plans to cut 7,800 jobs globally. Microsoft will keep open sites in Espoo and Tampere. Reference Link
|05:25 EDT||GSK||Novartis acquires all remaining rights to Ofatumumab from GSK |
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
|August 20, 2015|
|05:46 EDT||NOK||Nokia Networks expand use of WANdisco big data technology|
Subscribe for More Information